Geron Corporation Geron (NASDAQ: GERN) Release IMbark Phase 2 Data in Journal of Clinical Oncology Geron Corporation (NASDAQ: GERN) has released the data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper. The paper is entitled "Randomized, Single-Blind, Multicenter Phase II Study.
